Ceftazidime Powder for Solution bulk supplier for pharma manufacturers

Ceftazidime Powder For Solution 1 g, 2 g, 2.5 g, 3 g, 4 g Suppliers & Bulk Manufacturers

Available Forms: Powder for Solution

Available Strengths: 1 g, 2 g, 2.5 g, 3 g, 4 g

Reference Brands: Fortaz, Tazicef(US& EU)

Ceftazidime suspension inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis. It is effective against gram-negative bacteria, including Pseudomonas aeruginosa. Benefits include targeted, reliable oral therapy for pediatric or outpatient infections, rapid bacterial clearance, broad-spectrum activity, and convenience in managing serious infections in children.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ceftazidime suspension is approved in the EU and US for treating severe gram-negative bacterial infections, particularly in pediatric patients. In the EU, brands like Fortaz and generics are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on comprehensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality standards, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ceftazidime suspension, ensuring adherence to European and US standards for safe, effective therapy in serious infections.

Ceftazidime Powder For Solution — third party manufacturing & bulk supply

Ceftazidime Powder For Solution 1 g, 2 g, 2.5 g, 3 g, 4 g is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ceftazidime Powder For Solution is supplied as Powder for Solution — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ceftazidime Powder For Solution listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ceftazidime Powder For Solution →

Back to Listing

Frequently Asked Questions

Ceftazidime is an antibiotic used to treat a wide range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and septicemia. It is especially effective against Gram-negative bacteria, including Pseudomonas aeruginosa.

Ceftazidime is made from the active pharmaceutical ingredient ceftazidime, which belongs to the third-generation cephalosporin class of antibiotics. It works by interfering with bacterial cell wall synthesis, leading to cell death.

Common trade names include Fortaz, Ceptaz, and Tazicef.

Ceftazidime is manufactured by multiple pharmaceutical companies worldwide. The original brand Fortaz is marketed by GlaxoSmithKline (GSK) in some regions, while generic versions are produced by various other manufacturers.

The generic name is ceftazidime.

Brand names include Fortaz, Ceptaz, and Tazicef, along with multiple regional generics.

Ceftazidime is manufactured in regulated pharmaceutical facilities in the USA, EU, UK, India, and other countries depending on the manufacturer and marketing authorization holder.